Successful Immunization of an Allogeneic Bone Marrow Transplant Recipient with Live, Attenuated Yellow Fever Vaccine

Authors

  • Justin A. Yax DO, DTM&H,

    1. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
    Search for more papers by this author
  • Eileen C. Farnon MD,

    1. Arboviral Diseases Branch, Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA
    2. Present address: Special Pathogens Branch, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Search for more papers by this author
  • N. Cary Engleberg MD, DTM&H

    Corresponding author
    1. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
    2. Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, USA
    Search for more papers by this author

N. Cary Engleberg, MD, DTM&H, 3119N Taubman Center Box 0378, University of Michigan Hospitals, Ann Arbor, MI 48109, USA.
E-mail:cengleb@umich.edu

Abstract

Vaccination against yellow fever is effective, but available live virus vaccines are not recommended for use in immunocompromised or elderly patients. We report the successful and uneventful immunization of a 62-year-old man with a history of allogeneic bone marrow transplant and discuss evidence for this recommendation.

Ancillary